Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026
Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026
Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026
Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Doer Biologics Begins Phase II Study of DR10624 for Steatotic Liver Disease

Fineline Cube Apr 24, 2025

China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...

Company Deals Drug

Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies

Fineline Cube Apr 24, 2025

Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...

Company Deals

Genentech Collaborates with Repertoire Immune Medicines on Autoimmune Disease Therapies

Fineline Cube Apr 24, 2025

Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY) , announced a collaboration...

Company Deals

AstraZeneca Expands AI Partnership with Tempus AI and Pathos AI for Oncology Research

Fineline Cube Apr 24, 2025

UK pharmaceutical leader AstraZeneca (AZ, NASDAQ: AZN) has expanded its collaboration with US-based Tempus AI,...

Company

Boston Scientific Reports 20.9% Revenue Growth in Q1 2025 Financial Results

Fineline Cube Apr 24, 2025

US medical technology giant Boston Scientific Corporation (NYSE: BSX) released its Q1 2025 financial report,...

Company Medical Device

Roche Launches Navify Chest Pain Triage Algorithm With CE Mark

Fineline Cube Apr 24, 2025

Swiss healthcare giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it has received CE...

Policy / Regulatory

Trump Administration Considers Tying US Drug Prices to International Benchmarks

Fineline Cube Apr 24, 2025

Reuters reported that the Trump administration is exploring a policy to tie domestic drug prices...

Company Deals Drug

Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent

Fineline Cube Apr 24, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) has entered into a...

Company

PingAn Good Doctor Reports Q1 2025 Revenue Growth and Net Profit Turnaround

Fineline Cube Apr 24, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Medical Device

MicroPort MedBot Gains NMPA Clearance for Toumai’s Remote Surgery Across Departments

Fineline Cube Apr 24, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced receiving clearance from China’s National...

Company Deals

QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb

Fineline Cube Apr 24, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with...

Company

Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D

Fineline Cube Apr 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced a five-year investment plan totaling...

Company Deals

China Medical System Announces Spin-off of Dermavon for HKEX IPO

Fineline Cube Apr 23, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) has announced the spin-off of its dermatology-focused...

Company Drug

BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia

Fineline Cube Apr 23, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...

Company Drug

CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC

Fineline Cube Apr 23, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products...

Company Drug

CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia

Fineline Cube Apr 23, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) has obtained Investigational New Drug (IND) clearance from...

Company Drug

Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray

Fineline Cube Apr 23, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China’s National...

Company Drug

Biokin Receives NMPA Approval for CD33 ADC in AML Trial

Fineline Cube Apr 23, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...

Company Deals

Fujifilm Diosynth Secures $3 Billion US Manufacturing Pact with Regeneron

Fineline Cube Apr 23, 2025

FUJIFILM Diosynth Biotechnologies (FDB), a leading global contract development and manufacturing organization (CDMO) specializing in...

Company Deals

Hotgen Biotech Injects RMB 300 Million into Subsidiary Sungen Bio for Biologic R&D

Fineline Cube Apr 23, 2025

China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic capital injection plan, partnering...

Posts pagination

1 … 212 213 214 … 706

Recent updates

  • China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
  • Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
  • Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
  • Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
  • Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.